L Walch1, L Massade, M Dufilho, A Brunet, F Rendu. 1. UMR7131 CNRS/Université Pierre et Marie Curie (Paris 6), Hôpital Broussais, 102 rue Didot, 75014 Paris, France. laurence.walch@brs.ap-hop-paris.fr
Abstract
BACKGROUND: Although considered as an anti-inflammatory cytokine, interleukin-4 (IL-4) has been shown to be pro-atherogenic in mice models of atherosclerosis. OBJECTIVES: In order to elucidate this paradox, we have investigated the effects of IL-4 on characteristic atherogenic parameters in human umbilical vein endothelial cells (HUVECs): production of reactive oxygen species, expression of monocyte chemoattractant protein-1 (MCP-1) and nitric oxide (NO) bioavailability. RESULTS: Incubation of HUVECs with IL-4 resulted in an increased production of reactive oxygen species and extracellular O(2)(-)(*) measured using fluorogenic probes and Cytochrome c that was inhibited by superoxide dismutase or gp91ds-tat, a selective NADPH oxidase inhibitor. The latter also inhibited IL-4 induced over-expression of MCP-1 mRNA measured by classical and real time RT-PCR. Incubation of HUVECs with IL-4 reduced thrombin-induced NO release, detected by electrochemistry, an effect which was reversed by incubation with superoxide dismutase. Both production of reactive oxygen species and MCP-1 mRNA over-expression induced by IL-4 were fully inhibited by selective inhibitors of phosphatidyl inositol 3-kinase. CONCLUSION: The data demonstrate that IL-4 up-regulates the expression of MCP-1 and decreases NO bioavailability through activation of NADPH oxidase in endothelial cells. These results are in favor of a pro-inflammatory and pro-atherogenic effect of IL-4 in vascular tissues.
BACKGROUND: Although considered as an anti-inflammatory cytokine, interleukin-4 (IL-4) has been shown to be pro-atherogenic in mice models of atherosclerosis. OBJECTIVES: In order to elucidate this paradox, we have investigated the effects of IL-4 on characteristic atherogenic parameters in human umbilical vein endothelial cells (HUVECs): production of reactive oxygen species, expression of monocyte chemoattractant protein-1 (MCP-1) and nitric oxide (NO) bioavailability. RESULTS: Incubation of HUVECs with IL-4 resulted in an increased production of reactive oxygen species and extracellular O(2)(-)(*) measured using fluorogenic probes and Cytochrome c that was inhibited by superoxide dismutase or gp91ds-tat, a selective NADPH oxidase inhibitor. The latter also inhibited IL-4 induced over-expression of MCP-1 mRNA measured by classical and real time RT-PCR. Incubation of HUVECs with IL-4 reduced thrombin-induced NO release, detected by electrochemistry, an effect which was reversed by incubation with superoxide dismutase. Both production of reactive oxygen species and MCP-1 mRNA over-expression induced by IL-4 were fully inhibited by selective inhibitors of phosphatidyl inositol 3-kinase. CONCLUSION: The data demonstrate that IL-4 up-regulates the expression of MCP-1 and decreases NO bioavailability through activation of NADPH oxidase in endothelial cells. These results are in favor of a pro-inflammatory and pro-atherogenic effect of IL-4 in vascular tissues.
Authors: Josiane B S Braun; Jader B Ruchel; Alessandra G Manzoni; Fátima H Abdalla; Emerson A Casalli; Lívia G Castilhos; Daniela F Passos; Daniela B R Leal Journal: Mol Cell Biochem Date: 2017-11-29 Impact factor: 3.396
Authors: Farah Kako; Khatuna Gabunia; Mitali Ray; Sheri E Kelemen; Ross N England; Bashar Kako; Rosario G Scalia; Michael V Autieri Journal: Am J Physiol Cell Physiol Date: 2016-04-06 Impact factor: 4.249
Authors: James Richards; Khatuna Gabunia; Sheri E Kelemen; Farah Kako; Eric T Choi; Michael V Autieri Journal: J Mol Cell Cardiol Date: 2014-11-08 Impact factor: 5.000
Authors: Tracy Raymond; Matthew Schaller; Cory M Hogaboam; Nicholas W Lukacs; Rosemary Rochford; Steven L Kunkel Journal: Proc Am Thorac Soc Date: 2007-12
Authors: Iris Steinbrugger; Anton Haas; Richard Maier; Wilfried Renner; Monika Mayer; Christoph Werner; Andreas Wedrich; Yosuf El-Shabrawi; Otto Schmut; Martin Weger Journal: Mol Vis Date: 2009-03-27 Impact factor: 2.367